Andrew E. Arai, M.D.

Senior Investigator

Advanced Cardiovascular Imaging Group

NHLBI

Building 10, Room B1D416
10 Center Drive
Bethesda, MD 20814

301-496-3658

araia@nih.gov

Research Topics

Heart attacks are caused by the interruption of blood supply to a part of the heart, depriving cells of oxygen. Dr. Arai focuses his research on understanding and intervening in this process of myocardial infarction and ischemia. He is actively involved in developing new imaging methods, in particular magnetic resonance imaging (MRI) technologies that can be used in the clinic. The new technologies are validated in pre-clinical and clinical studies, which generate another cycle of new imaging methods—a process that leads to improved understanding of myocardial ischemia and infarction and practical new imaging methods suitable for diagnostic imaging.

His laboratory currently focuses on six major areas of clinical activity and translational research:

  • Assessment of the area at risk from myocardial infarction and myocardial salvage
  • Quantification of myocardial perfusion by MRI
  • Technical development of diagnostic cardiovascular MRI
  • Anatomical and physiological evaluation of coronary artery disease by cardiovascular computed tomography (CT)
  • Support for the NHLBI Advanced Cardiovascular Imaging Fellowship
  • Clinical and research support for cardiovascular MRI and cardiovascular CT at the NIH Clinical Center and at the Johns Hopkins Suburban Hospital in Bethesda, MD

Dr. Arai’s laboratory has successfully moved new technologies into the clinical setting. For example, he developed new MRI methodologies that are more reliable than product-level pulse sequences, validated these methodologies in animal models, and translated them into patients. He has also worked on quantifying the extracellular volume fraction of myocardium, a measurement with potential to detect diffuse myocardial fibrosis; cardiac fibrosis is an early sign in many cardiomyopathies, and a method of detection could have great prognostic value. His laboratory has also been a leader in using cardiac MRI to understand the role of edema within the area at risk (AAR) of an acute myocardial infarction; comparing the AAR to actual infarct size offers an additional level of clinical information, as it shows the effectiveness of intervention strategies.

Quantitative analysis of myocardial perfusion has recently documented that first-pass stress perfusion cardiac MRI scans can be quantified at a pixel level, which is equivalent to approximately 32 microliter volumes of myocardium. This resolution is more than an order of magnitude higher than currently possible by the physiological reference standard, microsphere methodology, and higher resolution than clinically available methods, which someday may enable much more nuanced patient diagnosis of coronary artery disease. These studies have benefited from new image acquisition methods and analysis techniques developed within Dr. Arai’s laboratory.

Biography

Andrew Arai earned a B.A. in biophysics from Cornell University in 1982 and a M.D. from the University of Illinois in 1986. He did his internship, residency, and fellowship at the Oregon Health Sciences Center between 1986 and 1993. He has been at the NIH since 1993 and became a tenured Investigator in 2004. At the NHLBI, he directs an advanced cardiac imaging research program that includes fellowship training. In 2001, Dr. Arai received a Presidential Early Career Award for Scientists and Engineers (PECASE), the highest honor bestowed by the U.S. Government on outstanding scientists and engineers beginning their independent careers. Dr. Arai has authored or coauthored over 150 papers or book chapters. He is president of the Society of Cardiovascular Magnetic Resonance and a member of the American Society of Clinical Investigation. As a member of the American Heart Association Council on Clinical Cardiology and Committee on Cardiac Imaging, he has helped develop various scientific advisory papers on cardiac imaging. He has also served as an expert advisor to the U.S. Food and Drug Administration (FDA).

Selected Publications

  1. Kellman P, Wilson JR, Xue H, Bandettini WP, Shanbhag SM, Druey KM, Ugander M, Arai AE. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. J Cardiovasc Magn Reson. 2012;14:64.

  2. Schelbert EB, Cao JJ, Sigurdsson S, Aspelund T, Kellman P, Aletras AH, Dyke CK, Thorgeirsson G, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Arai AE. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012;308(9):890-6.

  3. Hsu LY, Groves DW, Aletras AH, Kellman P, Arai AE. A quantitative pixel-wise measurement of myocardial blood flow by contrast-enhanced first-pass CMR perfusion imaging: microsphere validation in dogs and feasibility study in humans. JACC Cardiovasc Imaging. 2012;5(2):154-66.

  4. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF Jr, Arai AE. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113(15):1865-70.

  5. Nielles-Vallespin S, Khalique Z, Ferreira PF, de Silva R, Scott AD, Kilner P, McGill LA, Giannakidis A, Gatehouse PD, Ennis D, Aliotta E, Al-Khalil M, Kellman P, Mazilu D, Balaban RS, Firmin DN, Arai AE, Pennell DJ. Assessment of Myocardial Microstructural Dynamics by In Vivo Diffusion Tensor Cardiac Magnetic Resonance. J Am Coll Cardiol. 2017;69(6):661-676.


This page was last updated on September 13th, 2017